Venture Capital Access Online | The eMarketplace for the Venture Capital Industry

 

Bookmark and Share   

Home

Marketplace
Database
Deals
News
Store
Resources
Contact Us

 

 

 

News

VCPro Database 2014 (17th Edition) Now Available! Newly released


Venture Capital Deals Spreadsheet Now Available Newly released


 

Dermira Completes $51 Million Financing and Expands Management Team and Board of Directors

REDWOOD CITY, Calif., August 19, 2014-- Dermira, a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients, today announced that it has completed a $51 million Series C financing. Existing investors Bay City Capital, New Enterprise Associates (NEA), Canaan Partners and UCB S.A. were joined by new investors Apple Tree Partners, Aisling Capital, Rock Springs Capital, Sabby Capital and other healthcare investors, in the transaction. Leerink Partners LLC acted as the exclusive placement agent for the financing. Fenwick & West LLP acted as legal advisor to Dermira.

Dermira also announced key executive appointments with Andrew Guggenhime as Chief Operating Officer and Chief Financial Officer, Christine Conroy as Senior Vice President, Regulatory Affairs and Christine Ring as Vice President, Legal. In addition, Dermira has expanded its board of directors with the appointments of Dr. David E. Cohen, Matthew Fust, Mark McDade and William Ringo.

Management Additions

Andrew Guggenhime, Chief Operating Officer and Chief Financial Officer, oversees Dermira’s financial, corporate development, human resources, legal, and other administrative functions. Prior to joining Dermira, Andrew served as Chief Financial Officer for CardioDx, where he remains on the board of directors, as well as other healthcare companies including Calistoga Pharmaceuticals and Facet Biotech.

Christine Conroy, Senior Vice President of Regulatory Affairs, is responsible for Dermira’s regulatory affairs strategy and function. Christine previously served as Senior Vice President of Regulatory Affairs and Quality Assurance at Affymax, where she held regulatory leadership positions for nine years. Prior to Affymax, Christine held regulatory positions at Genitope, Roche Global Development and Syntex.

Christine Ring, Vice President, Legal, is responsible for the Company’s legal activities. Prior to joining Dermira, Christine most recently served as Chief Intellectual Property Counsel and Senior Vice President, Technology Strategy & Licensing at Amyris. Prior to Amyris, Christine was the Director of Intellectual Property at Sunesis Pharmaceuticals and Senior Patent Attorney at Kosan Biosciences.

Board of Director Additions

Dr. David E. Cohen, M.D., M.P.H., previously served as a scientific advisor to the Company since its inception. David has held a variety of positions at the New York University School of Medicine, including as Chief of Allergy and Contact Dermatitis, Vice Chairman of Clinical Affairs, Director of Occupational and Environmental Dermatology, and the Charles C. and Dorothea E. Harris Professor of Dermatology.

Matthew Fust was most recently Executive Vice President and Chief Financial Officer at Onyx Pharmaceuticals. Matt also serves as a member of the board of directors of MacroGenics, Sunesis Pharmaceuticals and Ultragenyx Pharmaceutical.

Mark McDade currently serves as Executive Vice President, Established Brands, Solutions and Supply, at UCB S.A., which he joined in April 2008. Mark also serves as a member of the board of directors of Five Prime Therapeutics.

William Ringo serves as a senior advisor to Barclays Healthcare Group and as a strategic advisor to Sofinnova Ventures. Bill also serves as a member of the board of directors of Assembly Biosciences, Immune Design, Mirati Therapeutics and Sangamo Biosciences.

About Dermira

Dermira is a privately held specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients. Dermira’s portfolio of five product candidates targets significant market opportunities and includes three late-stage product candidates, Cimzia (certolizumab pegol), in development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe plaque psoriasis, DRM04, a topical treatment for hyperhidrosis, and DRM01, a topical sebum inhibitor for the treatment of acne. Dermira is headquartered in Redwood City, California. For more information, please visit www.dermira.com.

Contact:
Dermira
Andrew Guggenhime, 650-421-7200
Chief Operating Officer and Chief Financial Officer
info@dermira.com


News Index

Venture Capital Database

Venture Capital Deals Spreadsheet

 

 NEWS

Latest VC News
VC News Archive
News Search
Venture Capital Deals
RSS News Feed

List Your Firm

Entrepreneurs
Investors
Advisors

Venture Capital Database

VCPro Database
Download Trial
Buy Now

Venture Capital Deals

vcaDeals
Download Sample
Buy Now

VC Tools

VC Pitch
Private Placement Memorandum

Business Plan Tools

Free Business Plan Template
Business Plan Tools

 

 

Copyright © 1998-2014 Access InterComm  All rights reserved. 
Site Map | Privacy Statement | Legal Notice & Disclaimer